National Projects

COBIK is an excellent research and project management partner. We lead or cooperate in several international, national and industrial (commercial) projects.

ARRS L4-4277 Innovative production systems for vaccines and regenerative medicine

Laboratory for Bio-Analytics

Laboratry for Bio-Analytics (LBA) is cooperating in development of convective based supports for efficient chromatographic purification of cells, virus like particles and bacteriophages. Research is directed towards optimization of existing methacrylate monoliths and development of fractal chromatographic support. For purification of eukaryotic and prokaryotic cells a new generation of support will be developed, based on inorganic porous support, hollow fibres and macroporous chromatographic monoliths. In the frame of the project LBA is testing developed convective supports with cells, virus like particles and various bacteriophages.

MGRT, e-storitve, mOIDom

Laboratory for Control Systems

mOIDom is a web and mobile application of informational and advisory nature. It enables users to monitor energy consumption through interactive consulting, solving of interactive exercises and learning how to reduce a large part of operational costs. Users can also compare their consumption with the consumption of comparable apartments, learn about their energy efficiency class and also export the data. Application is user friendly, easy to use and free for households.

The aim of the application is to encourage energy and money savings in order to reduce environmental strain and at the same time to maximize energy efficiency of buildings.

The European Commission is initiating an energy assessment of buildings, to raise awareness of energy efficiency, which will also be reflected in the value of the property. With the use of the mOIDom application users will be able to figure out why their neighbors are more environmentally effective than they are and how to raise environmental competitiveness and save some money.

The application will be available in July or August 2013.

Manufacturing of biologics and vaccines in the form of proteins, DNA, and viruses is operationally and technologically challenging. Producing large molecules reproducibly on an industrial scale requires manufacturing capabilities with a previously unknown sophistication. Conventionally, the biologics manufacturing process is done in batch mode, where each production step starts and ends independently from the previous and following step. The biopharmaceutical industry is in the transition from batch processing to fully continuous processing, mainly to increase productivity, maximize flexibility, simplify scale-up and process transfers, increase robustness, and minimize cost of goods while still maintaining operational excellence. The main goal of BioPharm.Si programme, involving high tech and biotech Slovenian companies and excellent research institutions, is development of continuous manufacturing processes and innovative devices and services that will facilitate transition from batch to fully continuous manufacturing.

The project BioPharm.Si is co-financed by Ministry of Education, Science and Sport of Republic of Slovenia and European regional fund in amount of 5.972.371,63€.


Gene therapy is a therapeutic strategy using genes as therapeutic agents. During the therapy therapeutic gene is inserted into targeted cells with the goal to (i) Introduce a new gene into the cell to fight a disease, (ii) replace a mutated gene causing disease with a healthy copy of the gene, (iii) inactivate a mutated gene that is functioning improperly. Gene is delivered to the cells in form of vectors such as viruses or plasmid DNA. Plasmid DNA is commonly delivered to the cells by electroporation. Plasmid DNA intended for gene therapy applications is typically produced in bacteria Escherichia coli under Good Manufacturing Practice (GMP) regulations. Gene therapy therefore starts with selection of therapeutic gene, continues with insertion of this gene into the vector, which is followed by production of vector containing therapeutic gene, and delivering vector to patients. The project is co-financed by Ministry of Education, Science and Sport of Republic of Slovenia and European regional fund in amount of 1.998.414,50€.

Project is addressing gene therapy challenges from selection of therapeutic gene, to production and delivery to patients with innovative globally applicable solutions.



Coinvest Venture Days 2015

The Coinvest Venture Days bring together tech startups from ‘New Europe’* and global venture investors. In...

more »